March 10, 2022
Medexprim Appoints Alexandre Blanchot as Business Development Manager
Medexprim has appointed Alexandre Blanchot as Business Development Manager.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 10, 2022
Novartis Signs Initial Agreement with Carisma Therapeutics for the Manufacturing of HER 2 Targeted CAR-M Cell Therapy
Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
March 10, 2022
NEJM publication of Novartis Kisqali Data Shows Longest Median Overall Survival Ever Reported in HR+/HER2- Advanced Breast Cancer
The New England Journal of Medicine (NEJM) published data showing the Phase III MONALEESA-2 trial for NovartIs’s Kisqali (ribociclib) plus letrozole demonstrated a statistically significant improvement in overall survival.
March 9, 2022
Thermo Fisher Scientific Extends Collaboration with Symphogen to Advance Biopharmaceutical Discovery and Development
Thermo Fisher Scientific and Servier’s affiliate Symphogen have announced the continuation of their collaboration to provide biopharmaceutical discovery and development…
March 9, 2022
Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines
Novo Nordisk has expanded its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
March 9, 2022
Lutz Hilbrich Appointed as Senator to the Senate of Economy Europe
MiGenTra and ProBioGen have announced the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to…
March 9, 2022
SOBI’s and Sanofi’s Haemophilia A Drug Met the Primary and Key Secondary Endpoints
Swedish Orphan Biovitrum (SOBI) and Sanofi have announced positive top-line results from the pivotal XTEND-1 phase 3 study evaluating the…
March 8, 2022
Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT congress
Basilea Pharmaceutica Ltd. has reported that preclinical data on the single agent anti-cancer activity of the drug candidate BAL0891 have been presented at the Targeted Anticancer Therapies congress 2022 of the European Society of Medical Oncology (ESMO TAT 2022), which is taking place online March 7-8, 2022.
March 8, 2022
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an…
March 8, 2022
Publication of Definitive Interim Result for Vifor Pharma Tender Offer: CSL Behring AG Declares Offer Successful
CSL Behring AG, a wholly-owned subsidiary of global biotechnology leader CSL Limited has announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.